Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen N Davis

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|February 20, 2014
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetesStephanie A Stein, Elizabeth M Lamos, Stephen N Davis
Expert Opinion on Drug Safety|June 9, 2016
Cardiovascular effects of anti-diabetes drugsLisa M Younk, Elizabeth M Lamos, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|January 9, 2010
The role of glimepiride in the treatment of type 2 diabetes mellitusVanessa J Briscoe, Michelle L Griffith, Stephen N Davis
Circulation Research|April 11, 2015
DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibitionJixin Zhong, Andrei Maiseyeu, Stephen N Davis, et al.
Expert Opinion on Therapeutic Targets|February 6, 2023
Type 1 diabetes: key drug targets and how they could influence future therapeuticsYoon Kook Kim, Kashif M Munir, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|September 13, 2024
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetesLidiya Kukova, Kashif M Munir, Ahmed Sayeed, et al.
Expert Review of Clinical Pharmacology|April 22, 2021
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver diseaseElizabeth M Lamos, Megan Kristan, Maka Siamashvili, et al.
Expert Review of Endocrinology & Metabolism|February 23, 2011
Exercise-related hypoglycemia in diabetes mellitusLisa M Younk, Maia Mikeladze, Donna Tate, et al.
Expert Opinion on Investigational Drugs|March 9, 2019
Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney diseaseHugh Davis, Vanessa Jones Briscoe, Sofio Dumbadze, et al.
Diabetes|June 11, 2009
Effects of differing antecedent increases of plasma cortisol on counterregulatory responses during subsequent exercise in type 1 diabetesShichun Bao, Vanessa J Briscoe, Donna B Tate, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
Expert Opinion on Drug Metabolism & Toxicology|February 20, 2014
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetesStephanie A Stein, Elizabeth M Lamos, Stephen N Davis
Expert Opinion on Drug Safety|June 9, 2016
Cardiovascular effects of anti-diabetes drugsLisa M Younk, Elizabeth M Lamos, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|January 9, 2010
The role of glimepiride in the treatment of type 2 diabetes mellitusVanessa J Briscoe, Michelle L Griffith, Stephen N Davis
Circulation Research|April 11, 2015
DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibitionJixin Zhong, Andrei Maiseyeu, Stephen N Davis, et al.
Expert Opinion on Therapeutic Targets|February 6, 2023
Type 1 diabetes: key drug targets and how they could influence future therapeuticsYoon Kook Kim, Kashif M Munir, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|September 13, 2024
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetesLidiya Kukova, Kashif M Munir, Ahmed Sayeed, et al.
Expert Review of Clinical Pharmacology|April 22, 2021
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver diseaseElizabeth M Lamos, Megan Kristan, Maka Siamashvili, et al.
Expert Review of Endocrinology & Metabolism|February 23, 2011
Exercise-related hypoglycemia in diabetes mellitusLisa M Younk, Maia Mikeladze, Donna Tate, et al.
Expert Opinion on Investigational Drugs|March 9, 2019
Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney diseaseHugh Davis, Vanessa Jones Briscoe, Sofio Dumbadze, et al.
Diabetes|June 11, 2009
Effects of differing antecedent increases of plasma cortisol on counterregulatory responses during subsequent exercise in type 1 diabetesShichun Bao, Vanessa J Briscoe, Donna B Tate, et al.
Pageof 13